RUNX3 methylation drives hypoxia-induced cell proliferation andantiapoptosis in early tumorigenesis.

Lee, Sun Hee and Hyeon, Do Young and Yoon, Soo-Hyun and Jeong, Ji-Hak andHan, Saeng-Myung and Jang, Ju-Won and Nguyen, Minh Phuong and Chi, Xin-Ziand An, Sojin and Hyun, Kyung-Gi and Jung, Hee-Jung and Song, Ji-Joon andBae, Suk-Chul and Kim, Woo-Ho and

Inactivation of tumor suppressor Runt-related transcription factor 3 (RUNX3) plays an important role during early tumorigenesis. However, posttranslational modifications (PTM)-based mechanism for the inactivation of RUNX3 under hypoxia is still not fully understood. Here, we demonstrate a mechanism that G9a, lysine-specific methyltransferase (KMT), modulates RUNX3 through PTM under hypoxia. Hypoxia significantly increased G9a protein level and G9a interacted with RUNX3 Runt domain, which led to increased methylation of RUNX3 at K129 and K171. This methylation inactivated transactivation activity of RUNX3 by reducing interactions with CBFβ and p300 cofactors, as well as reducing acetylation of RUNX3 by p300, which is involved in nucleocytoplasmic transport by importin-α1. G9a-mediated methylation of RUNX3 under hypoxia promotes cancer cell proliferation by increasing cell cycle or cell division, while suppresses immune response and apoptosis, thereby promoting tumor growth during early tumorigenesis. Our results demonstrate the molecular mechanism of RUNX3 inactivation by G9a-mediated methylation for cell proliferation and antiapoptosis under hypoxia, which can be a therapeutic or preventive target to control tumor growth during early tumorigenesis.

iDeal ChIP-seq Kit for Transcription Factors

Share this article

October, 2020


Products used in this publication

  • ChIP kit icon
    iDeal ChIP-seq kit for Transcription Factors


  • CNET 2022
    Gif-Sur-Yvette, France
    Jul 4-Jul 6, 2022
 See all events


 See all news

The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics